Early-stage biotechs with limited funds must balance the need for quick data with building a solid IND package. The solution is to run two tracks in parallel: one for immediate R&D experiments and another dedicated to the methodical, long-term planning required for regulatory submission.
To avoid wasting limited funds, startups should first validate their target product profile with regulators and investors. This 'end in mind' approach allows them to work backward, defining the exact data packages needed and prioritizing only the experiments that directly contribute to that goal.
Building any biotech is incredibly hard, so trying to find an 'easy' problem is a fallacy. Instead, founders should choose a massive, impactful problem. The sheer scale of the mission provides the necessary motivation for the team to persist through the inevitable, extreme challenges of development.
The fastest way to de-risk a biotech concept is to actively try to 'kill' it. By pitching to experts and seeking critical feedback in competitions, founders can expose fatal flaws early. If the idea is invalidated, it saves years of wasted effort; if it survives, it's significantly stronger.
Founders often get trapped by immediate constraints like budget and resources, leading to incremental thinking. A simple prompt from a peer—'If you had a magic wand, what would you do?'—can break this mindset, forcing a focus on the ideal solution and revealing a truly disruptive path.